I have been a long time holder of this stock and
I am curious to know what the future holds for this
Co. Considering this is the only Biotech stock in my
portfolio I am not accustomed to this thing called "waiting
for the FDA". I venture back to this board
occasionally to read the extremely informative posts, but it
seems that this stock has, for all intensive purposes,
stalled. I guess my question that I pose for all board
readers is what "realistically" is in this company's
future? Are we headed down a management-laden path to the
sewer with sub-par drugs or is that same team of
professionals going to take us and the wonderful drugs to the
promise land. I know that I am throwing a temper tantrum
and should have more hope for the drugs and the
people who could benefit but I would like to see
something solid come out in a press release from the Co. So
please, someone give my portfolio and me some good news!
with this companies stock price being flat after
a while some investors will be forced to sell their
shares thus reducing the price of the stock.As most of
you know I don't go long on companies with negative
earnings per share(EPS
Buying by anyone in the open market, be it
insiders or just us patient souls does not prolong the
companies life. The money flows to the seller.
lasermate2 should know this, so quit talking HUMBUG , OK..
Seller's may have options to buy 500,000 sh but
he owns outright a fraction of that amount. Fact is
we would all be better off if he bought more at
these levels and had his own money at risk rather than
merely the lost opportunity of out of the money options.
At least Singh has the guts to buy sstock outright
that represents a far greater sacrifice than anything
Sellers has done.
I'd normally share your cynicism &
skepticism. Sellers already owns over 500,000 shares, and the
officers and directors together own over 8% of the company
according to the annual proxy statment.
If I had
that kind of investment, I'd be trying to make it grow
and busily diversify my protfolio all the
It's not quite gone yet.
I still feel
that the small amount of insider buying is done to
fool more people to buy.
Consider that the CEO
has a $500,000 per year paycheck along with who knows
what kind of bonus payouts. At $1 1/4 per share he
only buys 15000 shares? He should know where SCLN is
going. If the future seemed bright, I'd expect him to
load up with 50000 or more shares. On the other hand,
if the small share purchase extends the life of the
company by only a few months (by tricking us to buy),
then his paychecks will more than offset the purchase
of the 15000 shares. It's good business for all the
SCLN officers to make small stock puchases since
"insider buying" looks good.
Thanks. That is an interesting
What is going on in the world?
Schering-Plough is (was?) collaborating with SCLN in Japan but
seems to be taking other approaches elsewhere. What is
the reason SCLN is having trouble with this good
product? Zadaxin doesn't even get honorable mention in
most discussions about hepatitis or hepatitis drugs.
Neither BCHE nor GILD seem to know SCLN exists. Or are
I can see the pricing problem
with countries like China but presumably only the
wealthy can afford treatment there, anyway. Hope the
price stays up since a cheap product in China and an
expensive one in Japan could lead to "grey market" price
competition. I have an image of little grey men in the dark of
night navigating treacherous waters in small boats full
of the hope of making small fortunes by--you guessed
it--buy low, sell high.
My knowledge of the situation is this....zadaxin
is definitely effective, and so far is the only drug
that works anywhere near this well. Right now sales
have been in china for hepatitis C indications, not
for hep B as studied in the phase II trials released
2 days ago, but the efiicacy should be near the
same. The drug is only selling in a country where
medications are very inexpensive, thus low profits. I think
the million in sales is excellent given these things.
As time progresses and sales are begun in more
markets, as well as for the hep B indications, they should
go through the roof. However in my opinion this is
not what we are waiting for....sciclone recently
acquired worldwide rights to zadaxin, a pivitol piece that
was in the way of gaining a new collaboration. What I
think we can expect is announcement of a collaborator
in the next 1 1/2-3 months. This should drive the
price of the stock through the roof...
Agree, respect is earned. However, I respect the
RIGHT (not the person) to say anything you want
regardless of whether I respect the source. I have the
option of ignoring what I don't like or believe. A
certain amount of blather is tolerable and sometimes
entertaining. Think about it.
As for SHMN, the relevance
is that it is (almost) a one product company which
is experiencing a run-up in anticipation of an
approval in mid-1999. SCLN is a one product company. It
has Zadaxin on the market and CPX in the wings with
no real attention-getting panache and no respect.
There are not many one-product companies out there in
the Biotech world. SCLN should be doing better. Is it
"undiscovered?" Is it a financial wallflower? Has it no sex
appeal? SHMN is sexy because it uses rain forest
ingredients and has tribal medicine men as advisors. Its
financing is equally exotic.
Meanwhile, BCHE has
gotten approval in the US for lamivudane for hepatitis
without showing real efficacy. SCLN's trials around the
world (if I read them right) show efficacy in
combination with interferon that exceeds treatment with
interferon alone. How does everyone else read that? If so,
why isn't Zadaxin getting a real push?